Built to provide research that’s more actionable and strategically valuable, The Business Research Company’s 2026 market reports include market attractiveness analysis, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, broader supply chain intelligence, emerging startup tracking, and in-depth product insights.
Cell-Based Ophthalmic Therapies Market Growth From $1.79 Billion In 2026 To $3.78 Billion By 2030 At A CAGR Of 20.5%
The cell-based ophthalmic therapies market has experienced significant expansion in recent years. This market is projected to grow from $1.48 billion in 2025 to $1.79 billion in 2026, achieving a compound annual growth rate (CAGR) of 20.9%. Historically, this growth can be attributed to factors such as limited treatment options for degenerative eye diseases, the growing prevalence of retinal and corneal disorders, an increasing aging population, rising awareness of regenerative medicine, and the expansion of ophthalmic research infrastructure.
The cell-based ophthalmic therapies market size is projected to undergo substantial expansion in the coming years. It is forecast to grow to $3.78 billion in 2030 at a compound annual growth rate (CAGR) of 20.5%. This anticipated growth throughout the forecast period stems from advancements in stem cell and gene editing technologies, escalating investment in regenerative ophthalmology, an increase in regulatory approvals for cell-based therapies, a rising demand for enduring vision restoration solutions, and the proliferation of specialized ophthalmic treatment centers. Significant trends observed during this period include the wider acceptance of stem cell and gene therapies for vision restoration, a heightened focus on regenerative treatments for retinal and corneal disorders, an increase in clinical trials for cell-based ophthalmic therapies, the broadening of personalized and precision ophthalmic treatments, and better long-term outcomes compared to conventional ophthalmic therapies.
Get A Free Sample Report With In-Depth Market Insights:
Cell-Based Ophthalmic Therapies Market Demand Drivers Opening New Revenue Streams
The rising occurrence of ophthalmic disorders is projected to fuel the expansion of the cell-based ophthalmic therapies market in the future. Ophthalmic disorders encompass diseases or conditions impacting the eyes, resulting in vision difficulties or harm to eye health. The prevalence of these disorders is increasing as the aging population faces a heightened risk of age-related eye diseases, leading to vision impairment with longer life expectancies. Cell-based ophthalmic therapies aim to repair or substitute damaged retinal and ocular cells to restore vision and prevent further deterioration, while also encouraging regeneration and enhancing overall eye function. For instance, in August 2024, the Welsh Government, a UK-based government agency, reported that ophthalmology departments in Wales recorded over 35,000 admissions in 2023-24, which signifies a 5.8% increase from 2022-2023. Therefore, the growing prevalence of ophthalmic disorders is driving the growth of the cell-based ophthalmic therapies market.
Cell-Based Ophthalmic Therapies Market Segmentation And Category Overview
The cell-based ophthalmic therapies market covered in this report is segmented –
1) By Therapy Type: Stem Cell Therapy, Gene Therapy, Tissue Engineering
2) By Application: Retinal Disorders, Corneal Disorders, Glaucoma, Other Applications
3) By End-User: Hospitals, Ophthalmic Clinics, Research Institutes, Other End-Users
Subsegments:
1) By Stem Cell Therapy: Embryonic Stem Cell Therapy, Mesenchymal Stem Cell Therapy, Induced Pluripotent Stem Cell Therapy, Retinal Pigment Epithelium Cell Therapy, Limbal Stem Cell Therapy
2) By Gene Therapy: Viral Vector-Based Gene Therapy, Non-Viral Vector Based Gene Therapy, In-Vivo Gene Therapy, Ex-Vivo Gene Therapy, Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)-Based Gene Therapy
3) By Tissue Engineering: Bioengineered Corneal Tissue, Amniotic Membrane Transplantation, Hydrogel-Based Scaffolds, Synthetic Polymer Scaffolds, Decellularized Tissue Constructs
Cell-Based Ophthalmic Therapies Market Trends Powering Strategic Industry Growth
Major companies operating in the cell-based ophthalmic therapies market are concentrating on developing advanced treatments, such as allogeneic cell therapy, to address unfulfilled medical needs in managing corneal endothelial diseases. Allogeneic cell therapy refers to a therapeutic approach utilizing stem cells or other cells donated by a genetically distinct individual of the same species to repair or replace damaged tissues or treat various diseases. For instance, in September 2024, Aurion Biotech, Inc., a US-based clinical-stage biotechnology company, announced the commercial launch of Vyznova (neltependocel) in Japan. This product is designed for the treatment of bullous keratopathy, a severe condition affecting the corneal endothelium. Vyznova is recognized as the first approved allogeneic cell therapy specifically targeting corneal endothelial disease, having secured both regulatory and reimbursement approvals in Japan.
Cell-Based Ophthalmic Therapies Market Competitive Analysis Of Leading Industry Participants
Major companies operating in the cell-based ophthalmic therapies market are F. Hoffmann-La Roche Ltd., Bayer AG, Novartis AG, Astellas Pharma Inc., Sumitomo Pharma Co. Ltd., Healios K.K., Lineage Cell Therapeutics, Pandorum Technologies Pvt. Ltd., Neurotech Pharmaceuticals Inc., Coave Therapeutics SAS, jCyte Inc., Eyestem Research Pvt. Ltd., Opsis Therapeutics, Regenerative Patch Technologies LLC, Emmetrope Ophthalmics LLC, GenSight Biologics S.A., MEDIPOST Co. Ltd., Riken, Luxa Biotechnology Inc.
View The Full Cell-Based Ophthalmic Therapies Market Report:
Cell-Based Ophthalmic Therapies Market Leading Geography: Which Region Contributes The Most Revenue?
North America was the largest region in the cell-based ophthalmic therapies market in 2025. The regions covered in the cell-based ophthalmic therapies market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Reach Out To Our Team:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
